Jurnal Penelitian Kesehatan Suara Forikes
Vol 13, No 1 (2022): Januari 2022

Perbandingan Angiotensin II Receptor Blocker Candesartan vs Termisartan vs Valsartan pada Monitoring Tekanan Darah Pasien Chronic Kidney Disease

Selly Septi Fandinata (Diploma III Farmasi, Akademi Farmasi Surabaya)
Rizky Darmawan (Diploma III Farmasi, Akademi Farmasi Surabaya)



Article Info

Publish Date
31 Jan 2022

Abstract

 Hypertension is a health problem that needs to be taken seriously because it is the most powerful killer disease in the world. Blood pressure is a determining factor to achieve and target BP. The recommended antihypertensive guidelines are ACEI, ARB, diuretic, CCB or B-blocker. ARBs have a cardiorenal protective effect. This study aims to compare the effectiveness of blood pressure drugs valsartan, termisartan and candesartan in hypertensive patients with chronic kidney disease. This study was a prospective observational cohort study by measuring blood pressure before and after at the 1st and 6th months and then processed using statistical analysis of the independent t-test and Wilcoxon. The results of this study obtained data as many as 72 patients who met the inclusion criteria consisting of 24 patients (candesartan), 27 patients (termisartan) and 21 patients (valsartan). The candesartan therapy group, the average difference in systolic decline was 18.46±16.14 mmHg and diastolic 2.04±15.16 mmHg with systolic pressure p-value = 0.000, diastolic p value = 0.217. Termisartan therapy had an average difference in systolic pressure reduction of 18.19±12.12 mmHg and diastolic pressure of 9.44±8.01 mmHg with systolic p-value = 0.000 and diastolic p-value = 0.000. The valsartan therapy group averaged a difference in systolic decrease of 0.14±1.2 mmHg, diastolic 2.71±2.84 mmHg with systolic pressure p-value = 0.766 and diastolic p-value = 0.102. So that of the three antihypertensive drugs, the most effective ARB in lowering systolic and diastolic blood pressure is telmisartanKeywords: blood pressure; termisartan; chronic kidney disease ABSTRAK Hipertensi merupakan masalah kesehatan yang perlu ditangani secara serius karena merupakan penyakit pembunuh paling dahsyat di dunia. Tekanan darah merupakan faktor penentuan agar tercapai dan target TD. Pedoman antihipertensi direkomendasikan yaitu ACEI, ARB, diuretik, CCB atau B-blocker. ARB memiliki efek protektif kardiorenal. Penelitian ini bertujuan untuk mengetahui perbandingan efektifitas tekanan darah obat valsartan, termisartan dan candesartan pada pasien hipertensi dengan chronic kidney disease. Penelitian ini merupakan penelitian kohort pengambilan data secara observasional prospektif dengan mengukur tekanan darah sebelum sesudah pada bulan ke 1 dan ke 6 kemudian diolah menggunakan analisa statistika uji t-independent dan Wilcoxon. Hasil penelitian ini didapatkan data sebanyak 72 pasien yang memenuhi kriteria inklusi terdiri 24 pasien (candesartan), 27 pasien (termisartan) dan 21 pasien (valsartan). Kelompok terapi candesartan, rata-rata selisih penurunan sistolik 18,46±16,14 mmHg dan diastolik 2,04±15,16 mmHg dengan tekanan sistolik nilai p = 0,000, diastolik nilai p = 0,217. Terapi termisartan rata-rata selisih penurunan tekanan sistolik 18,19±12,12 mmHg dan diastolik 9,44±8,01 mmHg dengan sistolik nilai p = 0,000 dan diastolik nilai p = 0,000. Kelompok terapi valsartan rata-rata selisih penurunan sistolik 0,14±1,2 mmHg, diastolik 2,71±2,84 mmHg dengan tekanan sistolik nilai p = 0,766 dan diastolik nilai p = 0,102. Sehingga dari ketiga obat anhipertensi golongan ARB yang paling efektif dalam menurunkan tekanan darah sistolik dan diastolik adalah telmisartan.Kata kunci: tekanan darah; termisartan; gagal ginjal kronik

Copyrights © 2022






Journal Info

Abbrev

sf

Publisher

Subject

Health Professions Medicine & Pharmacology Nursing Public Health

Description

Journal of Health Research "Forikes Voice" is a medium for the publication of articles on research and review of the literature. We accept articles in the areas of health such as public health, medicine, nursing, midwifery, nutrition, pharmaceutical, environmental health, health technology, clinical ...